<DOC>
	<DOCNO>NCT00460551</DOCNO>
	<brief_summary>The purpose study investigate treatment zalutumumab combination chemotherapy radiotherapy ( chemo-radiation ) lead prolonged life patient lung cancer compare patient treat chemo-radiation alone .</brief_summary>
	<brief_title>Zalutumumab Combination With Chemo-Radiation Certain Type Lung Cancer</brief_title>
	<detailed_description>Originally study plan Part 1A , Part 1B Part 2 . Part 1A one arm zalatumumab fix dose 8 mg/kg . Part 1B planned zalutumumab dose-titration Part 2 add comparator . The trial prematurely close enrolment patient enrol Part 1A due publish result show increased toxicity induction chemotherapy without survival benefit .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>NSCLC stage IIIAIIIB Performance status 0 1 ( Zubrod WHO Scale ) Evidence metastasis either separate lobe lung , extra thoracic Patients high risk radiation pneumonitis compromise lung function Estimated life expectancy le 3 month Prior chemotherapy lung cancer Prior radiotherapy chest Prior surgery curative intent lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>